clinical-collaboration-with-Amgen

Boehringer Ingelheim Enters Clinical Collaboration with Amgen to Study BI 1701963, a SOS1::pan-KRAS Inhibitor, in Combination with LUMAKRAS ™ (sotorasib), a KRASG12C InhibitorCombination of leading SOS1::pan-KRAS inhibitor with the first US FDA approved KRASG12C inhibitor has the potential to demonstrate additional therapeutic benefit for people living with KRAS G12C mutated cancers  The new clinical partnership adds to Boehringer Ingelheim ’s comprehensive program investigating combinations of its SOS1::pan-KRAS inhibitor, BI 1701963 with potentially synergistic approaches
Source: Boehringer Ingelheim Corporate News - Category: Research Source Type: news